arrow
返回
C

Clare L. Scott

walter and eliza hall institute of medical research, parkville, vic, australia

81H指数
503论文数
3.9W被引数
收录论文 125
发表时间
Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial奥拉帕利、度伐利尤单抗和环磷酰胺,以及铂敏感卵巢癌的预后血液特征:随机Ⅱ期SOLACE2试验
err2025-11-05
err0
errOAAI
errChee Khoon Lee; Apriliana E. R. Kartikasari; Nirashaa T. Bound; Katherine E. Francis; Kristy Shield-Artin; Justin Bedo; Ksenija Nesic; Katrina Diamante; Rachel L. O’Connell; Mutsa Madondo; Momodou Cox; Claire Davies; Cyril Deceneux; Georgia Goodchild; Andrew Jarratt; Emily Cassar; Hina Amer; U. G. Imalki U. Kariyawasam; Yeh Chen Lee; Janine Lombard; Sally Baron-Hay; Yoland Antill; Catherine Shannon; Sudarshan Selva-Nayagam; Philip Beale; Danka Zebic; Sandy Simon; Anneliese Linaker; Michael A. Quinn; Anthony T. Papenfuss; Matthew J. Wakefield; Cassandra J. Vandenberg; Michael Friedlander; Clare L. Scott; Magdalena Plebanski
err分享
err收藏
The antibody-drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models靶向ROR1的抗体药物偶联物NBE-002在高分级浆液性卵巢癌的体外模型中具有活性。
err2025-04-21
err0
errOAAI
errDongli Liu; Cassandra J. Vandenberg; Patrizia Sini; Lorenz Waldmeier; Rosa Baumgartinger; Laura Pisarsky; Georg Petroczi; Gayanie Ratnayake; Clare L. Scott; Caroline E. Ford
err分享
err收藏
Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody-drug conjugates, show activity in poor prognosis gynaecological cancer modelsFarletuzumab ecteribulin和MORAb-109,靶向叶酸受体α和间皮素的抗体-药物偶联物,在预后不良的妇科癌症模型中显示出活性。
err2025-03-12
err0
errOAAI
errNesic, Ksenija; Rybinski, Katherine; Ratnayake, Gayanie; Ho, Gwo-Yaw; Lim, Ratana; Radke, Marc; Neagle, Chloe; Swisher, Elizabeth M.; Wakefield, Matthew J.; Barker, Holly E.; Furuuchi, Keiji; Scott, Clare L.; Vandenberg, Cassandra J.
err分享
err收藏
Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80)Dodarlimab单独或联合贝伐单抗与非铂类化疗在复发性妇科透明细胞癌中的II期随机研究 (DOVE/APGOT-OV7/ENGOT-ov80)
err2025-01-01
err0
PREAI
errLee, Jung-Yun; Tan, David; Ray-Coquard, Isabelle; Lee, Jung Bok; Kim, Byoung Gie; Van Nieuwenhuysen, Els; Huang, Ruby Yun-Ju; Tse, Ka Yu; Gonzalez-Martin, Antonio; Scott, Clare; Hasegawa, Kosei; Wilkinson, Katie; Yang, Eun Yeong; Lheureux, Stephanie; Kristeleit, Rebecca
err分享
err收藏
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes多久才算足够长?一项国际调查,探讨在铂敏感复发性卵巢癌患者中,使用PARP抑制剂维持治疗推荐时长与实践差异及长期结局的关系。
err2024-12-01
err0
PREAI
errHaggstrom, Lucy; Lee, Yeh Chen; Scott, Clare; Harter, Philipp; Woelber, Linn; Gourley, Charlie; McNeish, Iain A.; Ray-Coquard, Isabelle; Leary, Alexandra; Oza, Amit M.; Tinker, Anna; Gonzalez Martin, Antonio; Cecere, Sabrina Chiara; Pignata, Sandro; Colombo, Nicoletta; Yoshida, Hiroyuki; Marth, Christian; Rosengarten, Ora; Moore, Kathleen Nadine; Gomez-Garcia, Eva Maria; Tan, David
err分享
err收藏
Impact of chemotherapy on patients with mismatch repair deficient advanced endometrial carcinomas-a meta-analysis
err2024-10-21
err0
errOAAI
errTjokrowidjaja, Angelina; Kok, Peey-Sei; Antill, Yoland C.; Scott, Clare L.; Mileshkin, Linda R.; Friedlander, Michael L.; Lee, Chee K.
err分享
err收藏
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in platinum sensitive recurrent ovarian cancer and long-term outcomes“多久才算足够长?”一项国际调查,探讨在铂敏感复发性卵巢癌中使用PARP抑制剂维持治疗推荐时长方面的实践差异及长期结局。
err2024-09-01
err0
PREAI
errHaggstrom, L. R.; Lee, Y. C.; Scott, C. L.; Ledermann, J. A.; Gourley, C.; McNeish, I.; Amant, F.; Ray-Coquard, I. L.; Leary, A.; Oza, A. M.; Tinker, A.; Gonzalez-Martin, A.; Cecere, S. C.; Colombo, N.; Yoshida, H.; Marth, C.; Gomez Garcia, E. M.; Tan, D. S.; Moore, K. N.; Friedlander, M. L.
err分享
err收藏
SOLACE2: A phase II randomized trial of olaparib (O) and durvalumab (D) with or without low dose cyclophosphamide (LDCy) in platinum-sensitive recurrent ovarian cancer (PSROC)SOLACE2:一项关于奥拉帕利(O)和度伐利尤单抗(D)联合或未联合低剂量环磷酰胺(LDCy)治疗铂敏感复发性卵巢癌(PSROC)的II期随机试验
err2024-09-01
err0
PREAI
errScott, C. L.; Friedlander, M. L.; Francis, K.; Kartikasari, A. E. R.; Diamante, K.; Bound, N.; Davies, C.; O'Connell, R.; Lee, Y. C.; Lombard, J.; Baron-Hay, S. E.; Antill, Y.; Shannon, C.; Selva-Nayagam, S.; Beale, P. J.; Shield-Artin, K.; Wakefield, M.; Vandenberg, C.; Plebanski, M.; Lee, C. K.
err分享
err收藏
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
err2024-08-05
err0
errOAAI
errNesic, Ksenija; Krais, John J.; Wang, Yifan; Vandenberg, Cassandra J.; Patel, Pooja; Cai, Kathy Q.; Kwan, Tanya; Lieschke, Elizabeth; Ho, Gwo-Yaw; Barker, Holly E.; Bedo, Justin; Casadei, Silvia; Farrell, Andrew; Radke, Marc; Shield-Artin, Kristy; Penington, Jocelyn S.; Geissler, Franziska; Kyran, Elizabeth; Betsch, Robert; Xu, Lijun; Zhang, Fan; Dobrovic, Alexander; Olesen, Inger; Kristeleit, Rebecca; Oza, Amit; McNeish, Iain; Ratnayake, Gayanie; Traficante, Nadia; DeFazio, Anna; Bowtell, David D. L.; Harding, Thomas C.; Lin, Kevin; Swisher, Elizabeth M.; Kondrashova, Olga; Scott, Clare L.; Johnson, Neil; Wakefield, Matthew J.
err分享
err收藏
High-level tumour methylation of BRCA1 and RAD51C is required for homologous recombination deficiency in solid cancers
err2024-07-25
err2
errOAAI
errXu, Lijun; Liddell, Brett; Nesic, Ksenija; Geissler, Franziska; Ashwood, Lauren M.; Wakefield, Matthew J.; Scott, Clare L.; Waddell, Nicola; Kondrashova, Olga
err分享
err收藏
A risk-reward examination of sample multiplexing reagents for single cell RNA-Seq
err2024-03-01
err5
errOAAI
errBrown, Daniel, V; Anttila, Casey J. A.; Ling, Ling; Grave, Patrick; Baldwin, Tracey M.; Munnings, Ryan; Farchione, Anthony J.; Bryant, Vanessa L.; Dunstone, Amelia; Biben, Christine; Taoudi, Samir; Weber, Tom S.; Naik, Shalin H.; Hadla, Anthony; Barker, Holly E.; Vandenberg, Cassandra J.; Dall, Genevieve; Scott, Clare L.; Moore, Zachery; Whittle, James R.; Freytag, Saskia; Best, Sarah A.; Papenfussa, Anthony T.; Olechnowicza, Sam W. Z.; Macrailda, Sarah E.; Wilcox, Stephen; Hickey, Peter F.; Amann-Zalcenstein, Daniela; Bowden, Rory
err分享
err收藏
The role of aberrant DNA methylation in cancer initiation and clinical impacts
err2024-01-28
err6
errOAAI
errGeissler, Franziska; Nesic, Ksenija; Kondrashova, Olga; Dobrovic, Alexander; Swisher, Elizabeth M.; Scott, Clare L.; J. Wakefield, Matthew
err分享
err收藏
Patient and public involvement in preclinical and medical research: Evaluation of an established programme in a Discovery-Based Medical Research Institute
err2024-01-19
err1
errOAAI
errSmith, Robyn A.; Slocombe, Judith; Cockwill, Jo; Minas, Kathy; Kiossoglou, George; Gray, Katya; Lawrence, William; Iddles, Michelle; Scott, Clare; O'Reilly, Lorraine A.
err分享
err收藏
Molecular profiling of p53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches
err2023-10-01
err0
errOAAI
errBlanc-Durand, F.; Kramer, C.; Rouleau, E.; Vasseur, D.; Bosse, T.; de Boer, S.; Edmondson, R.; Powell, M.; Crosbie, E.; Singh, N.; McAlpine, J.; Mackay, H.; Pollock, P.; Mileshkin, L.; Scott, C. L.; Ngoi, N. Y. L.; Lim, Y. W.; Lim, S. E.; Tan, D. S.; Leary, A.
err分享
err收藏